SecProbe.io

Stored correspondence activity detail
Intelligence Terminal Search Probe Scores Topics Monthly Activity About

Correspondence Activity Detail

SAB Biotherapeutics, Inc. (SABS, SABSW) (CIK 0001833214) (SABS)
Activity window: Oct. 25, 2025 to Oct. 24, 2026

Back View Correspondence Compare Probe Scores Download Probe Score CSV

Export this company’s current score, component values, matched signals, and scoring date as a one-row CSV snapshot.

Probe Score Breakdown

Current total
1.5 / 10
Correspondence-letter component
1.0
AI sentiment component
0.5
Keyword-match component
0.0
Signal-match component
0.0
Notable 8-K modifier
0.0

The total combines correspondence volume, AI sentiment, matched keywords and signals, and a weighted 8-K adjustment, capped at 10.0. This is the 365-day v1 snapshot. Computed: Oct. 24, 2026. Latest filing activity: Jan. 5, 2026. These dates describe different events.

Correspondence Filings
1
Keyword Matches
0
Latest Activity
Jan. 5, 2026
Related 8-Ks
0

Matched Signals

No stored keyword or signal matches were recorded for this activity window.

Filings In This Window

DateFormSentimentUrgencySummaryOpen
Jan. 5, 2026 CORRESP Neutral/Informational Moderate SAB Biotherapeutics, Inc. has submitted a request to the SEC to accelerate the effective date of their Registration Statement on Form S-3, originally filed on December 29, 2025. T… Read Filing EDGAR
Jan. 2, 2026 UPLOAD Neutral/Informational Low The SEC correspondence dated January 2, 2026, informs Samuel J. Reich, CEO of SAB Biotherapeutics, Inc., that the SEC has not reviewed and will not review the company's registrati… Read Filing EDGAR

Notable 8-Ks In This Window

No notable 8-Ks were stored for this company in this activity window.